Fulvestrant (ICI 182,780): High-Affinity Estrogen Receptor Antagonist for ER-Positive Breast Cancer Research

Executive Summary: Fulvestrant (ICI 182,780) is a potent, high-affinity estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM, used extensively to study ER-positive breast cancer mechanisms (APExBIO product). It functions by binding to and degrading ER, leading to downregulation of ER-mediated signaling pathways and MDM2 protein expression (Peng Wang et al., 2021). Fulvestrant enhances the sensitivity of breast cancer cells to chemotherapeutics such as doxorubicin, paclitaxel, and etoposide. It is central in research on endocrine therapy resistance. Workflow parameters and solubility profiles are well-characterized, making Fulvestrant (ICI 182,780) a reproducible and reliable research tool.

Biological Rationale

Estrogen receptor (ER) signaling is a major driver in ER-positive breast cancer pathophysiology. ER activation modulates cellular proliferation, survival, and immune responses in both physiological and pathological settings. The clinical burden of ER-positive breast cancer is significant, prompting development of selective ER modulators and antagonists. Fulvestrant (ICI 182,780) is a synthetic steroidal estrogen antagonist that binds competitively to ERα and ERβ, blocking endogenous estrogen action (APExBIO). By degrading the ER protein, Fulvestrant disrupts downstream gene transcription, notably reducing oncogenic drivers such as MDM2 and cell cycle regulators. This mechanism is essential for sensitizing cancer cells to combination chemotherapy and for modeling resistance to endocrine therapies (see related: Fulvestrant Dossier—this article extends prior summaries with new quantitative benchmarks).

Mechanism of Action of Fulvestrant (ICI 182,780)

Fulvestrant (ICI 182,780) exhibits high-affinity binding to the estrogen receptor, with an IC₅₀ of 9.4 nM in biochemical assays (APExBIO). Upon binding, it induces conformational changes in ER, triggering ubiquitin-mediated proteasomal degradation. This process leads to a marked reduction in cellular ER levels and suppresses ER-dependent gene expression. In ER-positive human breast cancer cell lines such as MCF7 and T47D, Fulvestrant treatment reduces MDM2 protein expression, resulting in cell cycle arrest (G1 phase accumulation), apoptosis, and cellular senescence (Peng Wang et al., 2021). Fulvestrant also abrogates estrogen-mediated immune modulation, as shown by its ability to reverse estradiol-induced normalization of splenic CD4+ T cell proliferation in animal models of hemorrhagic shock.

Evidence & Benchmarks

• Fulvestrant achieves an IC₅₀ of 9.4 nM for ER antagonism in vitro (APExBIO).
• It induces >90% reduction in ER protein levels within 24–48 hours at 1–10 μM in MCF7 cells (Scientific Reports, 2021).
• Fulvestrant downregulates MDM2 protein, increasing sensitivity to chemotherapeutic agents, and promoting apoptosis (Mechanistic Insights Article—this article quantifies effect size and duration).
• In vivo, intramuscular injection at 250 mg/month inhibits tumor growth in ER-positive breast cancer xenografts (APExBIO).
• Fulvestrant (ICI 182,780) administration reverses estradiol-mediated immune modulation in splenic CD4+ T cells, as confirmed by flow cytometry and proliferation assays in rat models (Scientific Reports, 2021).

Applications, Limits & Misconceptions

Fulvestrant is primarily utilized in preclinical and clinical research focusing on ER-positive breast cancer, especially in studies of endocrine therapy resistance and combination chemotherapeutic efficacy. The compound's robust solubility in DMSO (≥30.35 mg/mL) and ethanol (≥58.9 mg/mL), coupled with its stability at -20°C, make it suitable for high-throughput and long-term experiments. Typical in vitro dosing ranges from 1–10 μM for up to 66 hours. In vivo, Fulvestrant is administered intramuscularly at clinical doses (e.g., 250 mg/month), with demonstrated tumor growth inhibition in mouse xenografts.

By causing sustained ER downregulation, Fulvestrant overcomes limitations of partial antagonists and is less prone to resistance via receptor mutation. It has been adopted as a reference antagonist in studies dissecting ER signaling and evaluating novel endocrine therapies.

Recent studies also highlight its immunomodulatory effects, such as reversing estrogen-mediated suppression of T cell proliferation (Advancing Breast Cancer Therapy Article—this article adds quantitative immune data).

Common Pitfalls or Misconceptions

• Fulvestrant is not effective in ER-negative breast cancer; its mechanism requires functional ER protein.
• It does not directly inhibit non-ER pathways, such as androgen or progesterone receptors.
• Fulvestrant is insoluble in water; improper solvent use may lead to precipitation or loss of activity.
• Short incubation times (<12 hours) may be insufficient for maximal ER degradation.
• It is not suitable for oral administration due to poor bioavailability; clinical use is via intramuscular injection.

Workflow Integration & Parameters

Preparation: Fulvestrant (ICI 182,780) is a solid compound supplied by APExBIO (SKU: A1428). It is soluble at ≥30.35 mg/mL in DMSO and ≥58.9 mg/mL in ethanol. Warming to 37°C and ultrasonic agitation can improve dissolution. Store at -20°C; stock solutions remain stable for several months.

In Vitro Use: Apply at 1–10 μM for durations up to 66 hours in ER-positive breast cancer cell lines (e.g., MCF7, T47D). Monitor ER degradation by immunoblotting at 24–48 hours post-treatment. Assess cell cycle, apoptosis, and chemosensitivity endpoints.

In Vivo Use: For xenograft models, inject 250 mg intramuscularly per month, as in clinical regimens. Monitor tumor volume and ER expression in tumor lysates.

For detailed workflows, see Transforming ER-Positive Breast Cancer Article—this article provides additional troubleshooting tips for high-throughput screening.

For product ordering and lot-specific documentation, visit the official Fulvestrant (ICI 182,780) product page from APExBIO.

Conclusion & Outlook

Fulvestrant (ICI 182,780) remains the reference standard for selective ER antagonism in breast cancer research. Its well-characterized pharmacology, robust antagonistic effect, and compatibility with diverse model systems make it indispensable for studies of ER signaling, endocrine therapy resistance, and chemo-sensitization. Ongoing research is expanding its role in immunomodulation and combinatorial regimens. APExBIO continues to supply high-purity Fulvestrant for academic and translational research worldwide.